Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer

Clinical Therapeutics

Volumn 21, Issue 9, 1999, Pages 1443-1455

  Marsh, Wallace A ^a   Rascati, Karen L ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Anemia; Cancer; End stage renal disease; Erythropoietin; Meta analysis

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; KIDNEY FAILURE; META ANALYSIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; REVIEW; SOLID TUMOR;

EID: 0032855365     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80003-X     Document Type: Article

References (58)

1. Denton TA, Diamond GA, Matloff JM, Gray RJ. Anemia therapy: Individual benefit and societal cost. Semin Oncol. 1994;21(Suppl 3):29-35.
2. Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med. 1990;89:432-435.
3. Nissenson AR. National cooperative rHu erythropoietin study in patients with chronic renal failure: A phase IV multi-center study. Am J Kidney Dis. 1991;18 (Suppl 1):24-33.
4. Lim VS, Kirchner PT, Fangman J, et al. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis. 1989;14:496-506.
5. Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells. 1993;11:88-94.
6. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992;19(Suppl 8):29-35.
7. Laporte JPH, Isnard F, Fenaux P, et al. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes. Contrib Nephrol. 1991;88:271-272.
8. Jacobs A, Culligan D, Bowen D. Erythropoietin and the myelodysplastic syndrome. Contrib Nephrol. 1991;88:266-270.
9. Oster W, Herrmann F, Gamm H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990;8:956-962.
10. Ruedin P, Bertschi AP, Chapuis B, et al. Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in haemodialysed patient. Nephrol Dial Transplant. 1993;8:315-318.
11. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89:67-71.
12. Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther. 1997;19:559-569.
13. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl Med. 1991;324:1362-1365.
14. Cho MK, Bero LA. Instruments for assessing the quality of drug studies published in the medical literature. JAMA. 1994;272:101-104.
15. Chalmers TC, Smith H, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2:31-49.
16. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;ii:1175-1177.
17. Casati S, Passerini P, Campise MR, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J. 1987;295:1017-1020.
18. Schaefer RM, Kuerner B, Zech M, et al. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Int J Artif Organs. 1988;11:249-254.
19. Urabe A, Takaku F, Mizoguchi H, et al. Effect of recombinant human erythropoietin on the anemia of chronic renal failure. Int J Cell Cloning. 1988;6:179-191.
20. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989;321:158-163.
21. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000.
22. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Intern Med. 1989;110:108-114.
23. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant. 1989;4:979-987.
24. Aronoff GR, Duff DR, Sloan RS, et al. The treatment of anemia with low-dose recombinant human erythropoietin. Am J Nephrol. 1990;10(Suppl 2):40-43.
25. Canaud B, Polito-Bouloux C, Garred LJ, et al. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients. Am J Kidney Dis. 1990;15:169-175.
26. McMahon LP, Dawborn JK. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. Am J Nephrol. 1990;10:404-408.
27. Duff DR, Golper TA, Sloan RS, et al. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. Am J Kidney Dis. 1991;18:60-64.
28. Sundal E, Businger J, Kappeler A. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. Nephrol Dial Transplant. 1991;6:955-965.
29. Teehan BP. US recombinant human erythropoietin predialysis study group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 1991;18:50-59.
30. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405-1416.
31. Corazza F, Bergmann P, Dratwa M, et al. Responsiveness to recombinant erythropoietin therapy in end-stage renal disease: An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors. Nephrol Dial Transplant. 1992;7:311-317.
32. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990;322:1693-1699.
33. Bowen D, Culligan D, Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol. 1991;77:419-423.
34. Hellstrom E, Birgegard G, Lockner D, et al. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol. 1991;47:355-360.
35. Hiroshima K, Bessho M, Jinnai I. Improvement in anemia by recombinant human erythropoietin in patients with myelodys-plastic syndrome and aplastic anemia. Contrib Nephrol. 1991;88:254-265.
36. Kurzrock R, Talpaz M, Estey E, et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia. 1991;5:985-990.
37. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991;9:2021-2026.
38. Rose EH, Rudnick SA, Abels RI, et al. Efficacy and safety of recombinant human erythropoietin in anemic patients with myelodysplastic syndromes. Leuk Res. 1991;15(Suppl):13. Abstract.
39. Schouten HC, Rhenen DJ, Wolf JTM, et al. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia. 1991;5:432-436.
40. Van Kamp H, Prinsze-Postema TC, Kluin PM, et al. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol. 1991;78:488-493.
41. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992;19(Suppl 8):29-35.
42. Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial. Blood. 1992;79:29-37.
43. Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 1992;84:98-103.
44. Rafanelli D, Grossi A, Longo G, et al. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia. 1992;6:323-327.
45. Verhoef GEG, Zachee P, Ferrant A, et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment. Ann Hematol. 1992;64:16-21.
46. Barlogie B. Treatment of the anemia of multiple myeloma: The role of recombinant human erythropoietin. Semin Hematol. 1993;30(Suppl 6):25-27.
47. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Cisplatin-associated anaemia treated with subcutaneous erythropoietin: A pilot study. Br J Cancer. 1993;67:156-158.
48. Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells. 1993;11:348-355.
49. Ludwig H, Leitgeb C, Fritz E, et al. Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer. 1993;29A(Suppl 2):8-12.
50. Stenke L, Wallvik J, Celsing F, Hast R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia. 1993;7:1324-1327.
51. Tsukuda M, Mochimatsu I, Nagahara T, et al. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother. 1993;36:52-56.
52. Vijayakumar S, Roach M, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys. 1993;26:721-729.
53. Zeigler ZR, Jones D, Rosenfeld CS, Shadduck RK. Recombinant human erythropoietin for treatment of myelodysplastic syndrome. Stem Cells. 1993;11:49-55.
54. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056-1063.
55. Gregoire G, Derderian F, Lorier JL. Selecting the language of the publications included in a meta-analysis: Is there a tower of babel bias? J Clin Epidemiol. 1995;48:159-163.
56. Hunter JE, Schmidt FL. Methods of Meta-Analysis. Newbury Park, Calif: Sage Publications, Inc.; 1990:495-496.
57. Rosenthal R. Meta-Analytic Procedures for Social Research. Newbury Park, Calif: Sage Publications, Inc; 1991:51.
58. Wolf FM. Meta-analysis: Quantitative Methods for Research Synthesis. Newbury Park, Calif: Sage Publications, Inc; 1986:49.